Epigenetics in cancer: Fundamentals and Beyond

Subhankar Biswas, C. Mallikarjuna Rao

Research output: Contribution to journalReview article

60 Citations (Scopus)

Abstract

Activation of oncogenes or the deactivation of tumor suppressor genes has long been established as the fundamental mechanism leading towards carcinogenesis. Although this age old axiom is vastly accurate, thorough study over the last 15 years has given us unprecedented information on the involvement of epigenetic in cancer. Various biochemical pathways that are essential towards tumorigenesis are regulated by the epigenetic phenomenons like remodeling of nucleosome by histone modifications, DNA methylation and miRNA mediated targeting of various genes. Moreover the presence of mutations in the genes controlling the epigenetic players has further strengthened the association of epigenetics in cancer. This merger has opened up newer avenues for targeted anti-cancer drug therapy with numerous pharmaceutical industries focusing on expanding their research and development pipeline with epigenetic drugs. The information provided here elaborates the elementary phenomena of the various epigenetic regulators and discusses their alteration associated with the development of cancer. We also highlight the recent developments in epigenetic drugs combining preclinical and clinical data to signify this evolving field in cancer research.

Original languageEnglish
Pages (from-to)118-134
Number of pages17
JournalPharmacology and Therapeutics
Volume173
DOIs
Publication statusPublished - 01-05-2017

Fingerprint

Epigenomics
Neoplasms
Carcinogenesis
Histone Code
Gene Targeting
Nucleosomes
Drug Industry
DNA Methylation
Tumor Suppressor Genes
MicroRNAs
Oncogenes
Research
Pharmaceutical Preparations
Drug Therapy
Mutation
Genes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{0093c4c72cb147e79241fee2308b5515,
title = "Epigenetics in cancer: Fundamentals and Beyond",
abstract = "Activation of oncogenes or the deactivation of tumor suppressor genes has long been established as the fundamental mechanism leading towards carcinogenesis. Although this age old axiom is vastly accurate, thorough study over the last 15 years has given us unprecedented information on the involvement of epigenetic in cancer. Various biochemical pathways that are essential towards tumorigenesis are regulated by the epigenetic phenomenons like remodeling of nucleosome by histone modifications, DNA methylation and miRNA mediated targeting of various genes. Moreover the presence of mutations in the genes controlling the epigenetic players has further strengthened the association of epigenetics in cancer. This merger has opened up newer avenues for targeted anti-cancer drug therapy with numerous pharmaceutical industries focusing on expanding their research and development pipeline with epigenetic drugs. The information provided here elaborates the elementary phenomena of the various epigenetic regulators and discusses their alteration associated with the development of cancer. We also highlight the recent developments in epigenetic drugs combining preclinical and clinical data to signify this evolving field in cancer research.",
author = "Subhankar Biswas and Rao, {C. Mallikarjuna}",
note = "cited By 5",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.pharmthera.2017.02.011",
language = "English",
volume = "173",
pages = "118--134",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

Epigenetics in cancer : Fundamentals and Beyond. / Biswas, Subhankar; Rao, C. Mallikarjuna.

In: Pharmacology and Therapeutics, Vol. 173, 01.05.2017, p. 118-134.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Epigenetics in cancer

T2 - Fundamentals and Beyond

AU - Biswas, Subhankar

AU - Rao, C. Mallikarjuna

N1 - cited By 5

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Activation of oncogenes or the deactivation of tumor suppressor genes has long been established as the fundamental mechanism leading towards carcinogenesis. Although this age old axiom is vastly accurate, thorough study over the last 15 years has given us unprecedented information on the involvement of epigenetic in cancer. Various biochemical pathways that are essential towards tumorigenesis are regulated by the epigenetic phenomenons like remodeling of nucleosome by histone modifications, DNA methylation and miRNA mediated targeting of various genes. Moreover the presence of mutations in the genes controlling the epigenetic players has further strengthened the association of epigenetics in cancer. This merger has opened up newer avenues for targeted anti-cancer drug therapy with numerous pharmaceutical industries focusing on expanding their research and development pipeline with epigenetic drugs. The information provided here elaborates the elementary phenomena of the various epigenetic regulators and discusses their alteration associated with the development of cancer. We also highlight the recent developments in epigenetic drugs combining preclinical and clinical data to signify this evolving field in cancer research.

AB - Activation of oncogenes or the deactivation of tumor suppressor genes has long been established as the fundamental mechanism leading towards carcinogenesis. Although this age old axiom is vastly accurate, thorough study over the last 15 years has given us unprecedented information on the involvement of epigenetic in cancer. Various biochemical pathways that are essential towards tumorigenesis are regulated by the epigenetic phenomenons like remodeling of nucleosome by histone modifications, DNA methylation and miRNA mediated targeting of various genes. Moreover the presence of mutations in the genes controlling the epigenetic players has further strengthened the association of epigenetics in cancer. This merger has opened up newer avenues for targeted anti-cancer drug therapy with numerous pharmaceutical industries focusing on expanding their research and development pipeline with epigenetic drugs. The information provided here elaborates the elementary phenomena of the various epigenetic regulators and discusses their alteration associated with the development of cancer. We also highlight the recent developments in epigenetic drugs combining preclinical and clinical data to signify this evolving field in cancer research.

UR - http://www.scopus.com/inward/record.url?scp=85012876705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012876705&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2017.02.011

DO - 10.1016/j.pharmthera.2017.02.011

M3 - Review article

AN - SCOPUS:85012876705

VL - 173

SP - 118

EP - 134

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -